SHANGHAI and MORRISVILLE, N.C., Dec. 18, 2024 /PRNewswire/ — Inceptor Bio, a leading innovator in cell therapy, and GRIT Bio, a clinical-stage immunotherapy developer, today announced a strategic partnership to advance IB-T101, a potentially best-in-class CAR-T therapy targeting solid tumors.
IB-T101, Inceptor Bio’s autologous CD70 CAR-T program, utilizes the proprietary OUTLAST™ platform to reprogram T cells for superior stemness, durability, and effector function in the hostile tumor microenvironment. The program targets clear cell Renal Cell Carcinoma (ccRCC), a cancer with significant unmet medical need and over 300,000 new cases annually worldwide.
“We are excited to partner with GRIT Bio to bring IB-T101 into the clinic and address the urgent need for effective solid tumor therapies,” said Dr. Matthias Schroff, CEO of Inceptor Bio. “This collaboration highlights the potential of our proprietary OUTLAST™ platform, and the data generated will play a critical role in advancing the program as we strive to deliver best-in-class therapies for patients.”
Dr. Mengyang Chong, Chief Business Officer of GRIT Bio, shared, “Partnering with Inceptor Bio allows us to bring a highly differentiated CAR-T program to patients. IB-T101 has the potential to transform the treatment landscape for solid tumors, and we are eager to contribute our expertise in clinical development and manufacturing to accelerate its progress.”
Under the terms of the agreement, Inceptor Bio will grant GRIT Bio an exclusive license for IB-T101 in China. GRIT Bio will oversee development, manufacturing, and commercialization. Inceptor Bio is eligible to receive milestone payments and royalties upon IB-T101 achieving certain response criteria and plans to leverage clinical data from this collaboration to support regulatory submissions and development in other regions.
This partnership represents a critical step in Inceptor Bio’s mission to validate the OUTLAST™ platform as a best-in-class approach for engineered T cell therapies and bring transformative treatments to patients worldwide.
About Inceptor Bio
Inceptor Bio, founded in May 2020 and headquartered in Research Triangle Park, NC, is dedicated to advancing next-generation cell and gene therapies to cure cancer. The company’s proprietary OUTLAST™ platform reprograms T cells to maintain stemness and effector function, addressing the unique challenges of treating solid tumors. Inceptor’s lead program, IB-T101, targets CD70 in clear cell Renal Cell Carcinoma (ccRCC) and represents a potentially best-in-class therapy. With a strong leadership team and strategic partnerships, Inceptor Bio is committed to advancing a pipeline of cutting-edge therapies to improve outcomes for patients with limited treatment options globally.
About GRIT Bio
Founded in 2019, GRIT Biotechnology is a leading cell therapy company dedicated to delivering transformative cancer treatments. GRIT specializes in Tumor-Infiltrating Lymphocyte (TIL) therapies, leveraging its proprietary technology platforms—StemTexp®, StaViral®, KOReTIL®, and ImmuT Finder®—to develop next-generation gene-edited TIL products.With over 100 experienced professionals and a state-of-the-art GMP manufacturing facility, GRIT is advancing a robust pipeline of innovative cell therapies designed to address the unmet needs of solid tumor patients.
https://www.prnewswire.com/news-releases/inceptor-bio-and-grit-bio-announce-strategic-partnership-to-advance-ib-t101-a-next-generation-solid-tumor-car-t-utilizing-the-outlast-platform-302334271.html

Check out our AAV CDMO service to expedite your gene therapy research
PackGene Biotech is a world-leading CRO and CDMO, excelling in AAV vectors, mRNA, plasmid DNA, and lentiviral vector solutions. Our comprehensive offerings span from vector design and construction to AAV, lentivirus, and mRNA services. With a sharp focus on early-stage drug discovery, preclinical development, and cell and gene therapy trials, we deliver cost-effective, dependable, and scalable production solutions. Leveraging our groundbreaking π-alpha 293 AAV high-yield platform, we amplify AAV production by up to 10-fold, yielding up to 1e+17vg per batch to meet diverse commercial and clinical project needs. Moreover, our tailored mRNA and LNP products and services cater to every stage of drug and vaccine development, from research to GMP production, providing a seamless, end-to-end solution.
Related News
Navega Therapeutics Receives $4 Million CIRM Grant to Advance Epigenetic Gene Therapy for Chronic Pain
SAN DIEGO, CA – February 4, 2025 – Navega Therapeutics, a pioneering biotechnology company developing cutting-edge epigenetic gene therapies, today announced a significant milestone with the receipt of a $4 million Translational Science grant from the California...
Akribion Therapeutics Secures €8 Million in Seed Financing to Advance Novel RNA-Guided Cell Depletion Technology
ZWINGENBERG, Germany, February 4, 2025 – Akribion Therapeutics, a biotechnology company pioneering a unique, RNA-guided, nuclease-based technology for programmable cell depletion, today announced the closing of an €8 million Seed financing round. The round was led by...
UF-Kure19 CAR-T Cell Therapy Demonstrates High CR Rates, Low Toxicity in R/R NHL
Treatment with UF-Kure19, a rapidly manufactured CAR T-cell therapy, led to complete responses (CR) and low toxicity in patients with relapsed/refractory non-Hodgkin lymphoma, according to data from a single-arm, mult-center phase 1 study (NCT05400109) presented at...
Opinion: Companies Vie to Develop a Hunter Syndrome Therapy That Reaches the Brain
Several companies—including JCR Pharmaceuticals, Denali Therapeutics and Regenxbio—have products in the pipeline that could improve treatment options for this rare disease. Hunter syndrome is a rare, X‐linked disease caused by a deficiency of the lysosomal enzyme...
Related Services

AAV Packaging Services
READ MORE

Off-the-Shelf AAV Products
READ MORE